Cost-utility ana lyses of natalizumab versus interferon beta-1a 44 mcg for rapidly evolving severe relapsing-remitting multiple sclerosis (RESRRMS) patients in Brazil

Authors
Category Primary study
JournalValue in Health
Year 2013
This article has no abstract
Epistemonikos ID: 2e683630c3ec4bc7590282b1c9bc33b419014beb
First added on: Feb 05, 2025